Pfizer Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Pfizer's estimated annual revenue is currently $69.3B per year.(i)
  • Pfizer's estimated revenue per employee is $714,396
  • Pfizer's current valuation is $308.4B. (January 2022)

Employee Data

  • Pfizer has 97061 Employees.(i)
  • Pfizer grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11830M486730%$2.7B$83B
#2
$32820M944426%N/A$182.4B
#3
$15.9M797%N/AN/A
Add Company

Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.

keywords:Biotechnology

N/A

Total Funding

97061

Number of Employees

$69.3B

Revenue (est)

7%

Employee Growth %

$308.4B

Valuation

N/A

Accelerator

Pfizer News

2022-04-20 - The case for testing Pfizer's Paxlovid for treating long COVID

Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...

2022-04-20 - Analysis: Demand for Pfizer's COVID pills lags around the world

Worldwide demand for Pfizer Inc's oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility...

2022-04-19 - The case for testing Pfizer's Paxlovid for treating long COVID

Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...

2021-11-24 - Pfizer : Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia

Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia Study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) - as well as a statistically significant r ...

2021-11-09 - Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commerc ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30740M972704%N/A
#2
$24790M98424-3%N/A
#3
$34920M1168941%N/A
#4
$19100M12056013%N/A
#5
$19100M1327109%N/A